Dynamics of the Motor Symptoms of Parkinson’s Disease on the Background of Chronic Bilateral Electrical Stimulation of the Subthalamic Nucleus Using Two Methods to Verify Target Structure

  • N. N. GubarevaEmail author
  • N. V. Fedorova
  • E. V. Bril’
  • A. A. Tomskii
  • A. A. Gamaleya
  • A. A. Poddubskaya
  • V. A. Shabalov
  • S. M. Omarova

Objectives. To determine the efficacy of electrical stimulation of the subthalamic nucleus using different methods to verify target structure in patients with Parkinson’s disease based on assessment of the dynamics of motor symptoms. Materials and methods. A total of 60 patients with PD with chronic bilateral electrical stimulation of the subthalamic nucleus (ES of the STN) were studied. Multichannel microelectrode recording (MER) was performed during neurostimulation electrode implantation surgery in 30 cases. Intraoperative MER was not performed in 30 cases. The control group consisted of 30 patients with PD who received only conservative medication-based treatment. Patient investigations used the Hoehn and Yahr scale, the Tinetti Balance and Mobility Scale (TBMS), the Unifi ed Parkinson’s Disease Rating Scale (UPDRS), the PDQ-39 quality of life self-assessment scale for Parkinson’s disease, and the Schwab and England Activities of Daily Living (ADL) scale. The levodopa equivalent daily dose (LEDD) was determined individually for each patient. Results and conclusions. ES of the STN was found to be effective when used in combination with MER in terms of effects on the severity of the main motor symptoms, motor complications, gait, and measures of quality of life and the activities of daily living. On the background of ES of the STN, patients of both surgical groups attained significant reductions in LEDD with marked improvements in the control of the motor symptoms of PD; significant decreases in the severity of motor fluctuation (50%) and peak dose iatrogenic dyskinesias (51%) were seen. Measures of quality of life and the activities of daily living while off medication improved significantly in both groups of patients receiving ES of the STN independently of the intraoperative target selection technique (75–100%) as compared with the control group.


Parkinson’s disease chronic bilateral electrical stimulation of the subthalamic nucleus microelectrode recording motor symptoms 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    G. Deuschl, M. Schüpbach, K. Knudsen, et al., “Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson’s disease: Concept and standards of the EARLYSTIM-study,” Parkinsonism Relat. Disord., 19, No. 1, 56–61 (2013), parkreldis.2012.07.004.Google Scholar
  2. 2.
    A. Machado, M. Deogaonkar, and S. Cooper, “Deep brain stimulation for movement disorders: Patient selection and technical options,” Cleve. Clin. J. Med., 79, Suppl. 2, 19–24 (2012), https://doi. org/10.3949/ccjm.79.s2a.04.Google Scholar
  3. 3.
    R. deSouza, E. Moro, A. Lang, and A. Schapira, “Timing of deep brain stimulation in Parkinson disease: A need for reappraisal?” Annals of Neurology 73, No. 5, 565–575 (2013), Scholar
  4. 4.
    P. Starr and J. Ostrem, “Commentary on ‘Adaptive deep brain stimulation in advanced Parkinson disease,’” Ann. Neurol., 74, No. 3, 447–448 (2013), Scholar
  5. 5.
    “Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease,” N. Engl. J. Med., 364, No. 9, 886 (2011),
  6. 6.
    A. Paffi , F. Camera, F. Apollonio, et al., “Numerical characterization of intraoperative and chronic electrodes in deep brain stimulation,” Front. Comput. Neurosci., 9 (2015), 10.3389/fncom. 2015.00002.Google Scholar
  7. 7.
    V. A. Shabalov, A. A. Tomskii, E. V. Bril’, and N. V. Fedorova, “Electrical stimulation of the subthalamic nucleus in Parkinson’s disease,” Zh. Vopr. Neirokhir. No. 3, 14–17 (2006).Google Scholar
  8. 8.
    C. Seifried, L. Weise, R. Hartmann, et al., “Intraoperative microelectrode recording for the delineation of subthalamic nucleus topography in Parkinson’s disease,” Brain Stimul., 5, No. 3, 378–387 (2012), Scholar
  9. 9.
    W. Gibb and A. Lees, “The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease,” J. Neurol. Neurosurg. Psychiatry, 51, No. 6, 745–752 (1988), Scholar
  10. 10.
    A. Hughes, Y. Ben-Shlomo, S. Daniel, and A. Lees, “What features improve the accuracy of clinical diagnosis in Parkinson’s disease: A clinicopathologic study,” Neurology, 42, No. 6, 1142–1142 (1992), Scholar
  11. 11.
    R. Postuma, D. Berg, M. Stern, et al., “MDS clinical diagnostic criteria for Parkinson’s disease,” Mov. Disord., 30, No. 12, 1591–1601 (2015), Scholar
  12. 12.
    J. Langston, H. Widner, C. Goetz, et al., “Core assessment program for intracerebral transplantations (CAPIT),” Mov. Disord., 7, No. 1, 2–13 (1992), Scholar
  13. 13.
    N. Hoehn and M. Yahr, “Parkinsonism: onset, progression, and mortality,” Neurology, 17, No. 5, 427–427 (1967), 1212/wnl.17.5.427.CrossRefGoogle Scholar
  14. 14.
    O. Lindvall, “Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson’s disease,” Arch. Neurol., 46, No. 6, 615 (1989), Scholar
  15. 15.
    M. Tinetti, “Performance-oriented assessment of mobility problems in elderly patients,” J. Am. Ger. Soc., 34, No. 2, 119–126 (1986), Scholar
  16. 16.
    C. Goetz, B. Tilley, S. Shaftman, et al., “Movement Disorder Societysponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results,” Mov. Disord., 23, No. 15, 2129–2170 (2008), Scholar
  17. 17.
    V. Peto, C. Jenkinson, R. Fitzpatrick, and R. Greenhall, “The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease,” Qual. Life Res., 4, No. 3, 241–248 (1995), Scholar
  18. 18.
    R. Schwab and A. England, “Parkinson’s disease,” J. Chron. Dis., 8, No. 4, 488–509 (1958), 90006-7.
  19. 19.
    S. Fahn, R. L. Elton, and members of the UPDRS Development Committee, “Unified Parkinson’s disease rating scale,” in: Recent Developments in Parkinson’s Disease, S. Fahn et al. (eds.), Macmillan Healthcare Information, Florham Park, NJ (1987), pp. 153–163,
  20. 20.
    C. Tomlinson, R. Stowe, S. Patel, et al., “Systematic review of levodopa dose equivalency reporting in Parkinson’s disease,” Mov. Disord., 25, No. 15, 2649–2653 (2010), Scholar
  21. 21.
    P. Blomstedt and M. Hariz, “Deep brain stimulation for movement disorders before DBS for movement disorders,” Parkinsonism Relat. Disord., 6, No. 7, 429–433 (2010), 2010.04.005.Google Scholar
  22. 22.
    H. Bronte-Stewart, C. Barberini, M. Koop, et al., “The STN beta-band profile in Parkinson’s disease is stationary and shows prolonged attenuation after deep brain stimulation,” Exp. Neurol., 215, No. 1, 20–28 (2009), Scholar
  23. 23.
    A. Benabid, S. Chabardes, J. Mitrofanis, and P. Pollak, “Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease,” Lancet Neurol., 8, No. 1, 67–81 (2009), https://doi. org/10.1016/s1474-4422(08)70291-6.Google Scholar
  24. 24.
    E. Lagrange, P. Krack, E. Moro, et al., “Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD,” Neurology, 59, No. 12, 1976–1978 (2002), Scholar
  25. 25.
    M. Lanotte, “Deep brain stimulation of the subthalamic nucleus: anatomical, neurophysiological, and outcome correlations with the effects of stimulation,” J. Neurol. Neurosurg. Psychiatry, 72, No. 1, 53–58 (2002), Scholar
  26. 26.
    J. Vesper, F. Klostermann, F. Stockhammer, et al., “Results of chronic subthalamic nucleus stimulation for Parkinson’s disease: a 1-year follow-up study,” Surg. Neurol., 57, No. 5, 306–311 (2002), https://

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • N. N. Gubareva
    • 1
    Email author
  • N. V. Fedorova
    • 1
  • E. V. Bril’
    • 1
  • A. A. Tomskii
    • 2
  • A. A. Gamaleya
    • 2
  • A. A. Poddubskaya
    • 2
  • V. A. Shabalov
    • 2
  • S. M. Omarova
    • 1
  1. 1.Russian Medical Academy for Continuing Professional EducationCenter for Extrapyramidal DiseasesMoscowRussia
  2. 2.Burdenko National Scientific and Applied Center for NeurosurgeryRussian Ministry of HealthMoscowRussia

Personalised recommendations